Tardive Dyskinesia Supportive Care Protocol
Primary Stack
Core supplements with strongest evidenceAntioxidant; some evidence for preventing worsening of TD; less effective for established TD
Supporting Studies (1)
Some studies show benefit for TD symptoms; may affect dopamine metabolism
Supporting Studies (1)
Supporting Stack
Additional supplements for enhanced resultsAnti-inflammatory; supports neuronal membrane health; may help with psychiatric symptoms
Supporting Studies (1)
May reduce TD symptoms; compete with phenylalanine at blood-brain barrier
Supporting Studies (1)
Antioxidant; neuroprotective; may help with TD symptoms
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Tardive dyskinesia (TD) is a movement disorder characterized by involuntary, repetitive movements, often of the face, tongue, and jaw. It typically develops as a side effect of long-term use of certain psychiatric medications, particularly older antipsychotics.
COMMON MOVEMENTS:
RISK FACTORS:
CRITICAL: TD requires medical management. This protocol is SUPPORTIVE ONLY.
MEDICAL TREATMENT:
PREVENTION:
* Vitamin E may help prevent worsening (less effective for established TD).
* Vitamin B6 has shown some benefit in small studies.
* Antioxidants may provide neuroprotective support.
Expected timeline: VMAT2 inhibitors show benefit within weeks. TD may be irreversible in some cases, especially if longstanding.
Clinical Perspective
Tardive Dyskinesia: Iatrogenic movement disorder from prolonged dopamine receptor-blocking agent (DRBA) exposure. Pathophysiology: dopamine receptor supersensitivity, oxidative stress, neurodegeneration. Prevalence: ~20-30% with long-term typical antipsychotic use; lower with atypicals. Risk factors: age, female sex, diabetes, mood disorders, longer exposure, higher doses.
CRITICAL: VMAT2 inhibitors (valbenazine, deutetrabenazine) are FDA-approved and effective. If possible, reduce/discontinue offending agent or switch to clozapine/quetiapine. TD can be irreversible - prevention through lowest effective dose and regular AIMS screening. Supplements have limited evidence - may provide modest adjunctive benefit but not primary treatment.
* Vitamin E (C-grade): Antioxidant. Cochrane: (PMID: 23075608). 400-1600 IU daily. May prevent worsening.
* Vitamin B6 (C-grade): Dopamine metabolism. Systematic review: (PMID: 27450775). 100-400mg daily.
* Omega-3 (C-grade): Membrane health. Review: (PMID: 27840029). 2-4g EPA+DHA daily.
* BCAAs (C-grade): Phenylalanine competition. Pilot studies: (PMID: 29430697). 222mg/kg/day.
* Melatonin (C-grade): Antioxidant. Review: (PMID: 28648359). 2-10mg at bedtime.
Assessment targets: AIMS score, patient-reported symptoms, functional impact, underlying psychiatric stability.
Protocol notes: VMAT2 inhibitors: valbenazine 40-80mg daily or deutetrabenazine 12-48mg/day; effective ~60% response rate; continue indefinitely. Medication review: can offending agent be reduced/stopped? Switch to clozapine or quetiapine if antipsychotic needed. AIMS: Abnormal Involuntary Movement Scale; screen regularly. Prevention: use lowest effective dose; prefer second-generation; regular monitoring. Irreversibility: early TD more likely to improve; established TD may be permanent. Spontaneous improvement: can occur; more likely with shorter exposure, younger age. Differential: drug-induced parkinsonism, chorea, stereotypies, withdrawal dyskinesia. Psychiatric stability: balance TD treatment with need for antipsychotic. Clozapine: lowest TD risk; may improve existing TD.